Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791984 | 1.00 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL1419721 | 1.00 | SCN4A (0.61) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL22229209 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL7757109 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL56787 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| SCHEMBL12789473 | 0.88 | SCN4A (0.53) | SCN4ATACR1 | |
| SCHEMBL90024 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL19312226 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL90002 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL2782707 | 0.83 | SCN4A (0.68) | SCN4ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | US | claimed |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | claimed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | claimed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | claimed |
| EP-1819330-A1 | 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY | Devgen N.V. (BE) | 2007-08-22 | — | — | EP | claimed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2006058905-A1 | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY | DEVGEN NV (BE) | 2006-06-08 | — | — | WO | claimed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | claimed |
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250145561-A1 | 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 | RESEARCH TRIANGLE INSTITUTE (US) | 2025-05-08 | — | — | US | disclosed |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
| US-5856579-A | Adduct salts of novel substituted benzylamines and a process for optically resolving them | AJINOMOTO CO., INC. (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0776883-A1 | Adduct salts of substituted benzylamine and a process for optically resolving them | Ajinomoto Co., Inc. (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | SCN4A 3698/4885TACR1 4332/4885 |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | SCN4A 3693/4885TACR1 4334/4885 |
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | SCN4A 2838/4885TACR1 292/4885 |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | SCN4A 10/4885TACR1 413/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | SCN4A 1191/4885TACR1 127/4885 |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | CNR2, CNR1, NPY4R | SCN4A 413/4885TACR1 116/4885 |
| US-20250145561-A1 | 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 | GPR88, GPR84, GPR139 | SCN4A 756/4885TACR1 572/4885 |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | KCNA5, KCNA1, KCNJ2 | SCN4A 96/4885TACR1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.